Search

Your search keyword '"Bearman, Scott I."' showing total 137 results
Start Over Author "Bearman, Scott I."
137 results on '"Bearman, Scott I."'

4. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer

Author

Flanigan, Robert C., Salmon, Sydney E., Blumenstein, Brent A., Bearman, Scott I., Roy, Vivek, McGrath, Patrick C., Caton, John R., Jr., Munshi, Nikhil, and Crawford, E. David

Subjects
Carcinoma, Renal cell -- Care and treatment, Interferon alpha -- Health aspects
Abstract

Patients with metastatic renal cell cancer who have the kidney removed and also take interferon alfa-2b have longer survival rates than those who only take interferon alfa-2b. Metastatic renal cell cancer is kidney cancer that has spread to other parts of the body.

Published
2001

14. Transplantation of ex vivo expanded cord blood

Author

Shpall, Elizabeth J, Quinones, Ralph, Giller, Roger, Zeng, Chan, Baron, Anna E, Jones, Roy B, Bearman, Scott I, Nieto, Yago, Freed, Brian, Madinger, Nancy, Hogan, Christopher J, Slat-Vasquez, Vicki, Russell, Peggy, Blunk, Betsy, Schissel, Deborah, Hild, Elaine, Malcolm, Janet, Ward, William, and McNiece, Ian K

Published
2002
Full Text
View/download PDF

15. Acute lung injury following treatment with high-dose cyclophosphamide, cisplatin, and carmustine: pharmacodynamic evaluation of carmustine

Author

Jones, Roy B., Matthes, Steven, Shpall, Elizabeth J., Fisher, James H., Stemmer, Salomon M., Dufton, Christopher, Stephens, Janet K., and Bearman, Scott I.

Subjects
Pharmacokinetics -- Research, Chemotherapy, Combination -- Adverse and side effects, Carmustine -- Adverse and side effects, Lungs -- Injuries, Health
Abstract

Background: Therapy with high-dose cyclophosphamide, cisplatin, and carmustine (BCNU) plus autologous bone marrow transplantation has been extensively studied as treatment for patients with stage II or III breast cancer who have a 70% or greater risk of developing metastatic disease. This therapy is being used in a cooperative intergroup phase III clinical trial. In the cyclophosphamide-cisplatin-BCNU regimen, cyclophosphamide and BCNU, but not cisplatin, have been reported to cause acute lung injury, suggesting that either cyclophosphamide or BCNU may contribute to this injury. Purpose: The purpose of this study was to analyze clinical and pharmacokinetic data from our ongoing phase II trials and to determine whether there is an association between BCNU pharmacokinetics and acute lung injury following cyclophosphamide-cisplatin-BCNU therapy. Methods: We performed a retrospective study of 38 patients treated following induction therapy or relapse, 29 with stage II-IV breast cancer and nine with intermediate and high-grade stage III-IV non-Hodgkin's lymphoma. These patients received therapy with cyclophosphamide at a dose of 1875 [mu]g/[m.sup.2] daily as a 1-hour intravenous infusion for 3 days, cisplatin at 55 mg/[m.sup.2] per day as a 72-hour continuous intravenous infusion, and BCNU at 600 mg/[m.sup.2] as a 2-hour infusion immediately following completion of the cisplatin infusion. Data from analysis of blood samples were used to calculate pharmacokinetic parameters for BCNU, and acute lung injury was determined on the basis of pulmonary function test results and histologic examination of lung biopsy specimens. Results: Our analysis showed that 20 (53%) of the 38 patients developed pulmonary injury following treatment. Twelve (60%) of the 20 had values for area under the curve (AUC) for BCNU concentration x time that exceeded 600 ([mu]g/mL) x minute, whereas only two (11%) of the 18 without pulmonary injury had values above this level (P

Published
1993

16. Bone Marrow Transplantation for Patients with Myelodysplasia: Pretreatment Variables and Outcome

Author

Appelbaum, Frederick R., Barrall, Janet, Storb, Rainer, Fisher, Lloyd D., Schoch, Gary, Ramberg, Robert E., Shulman, Howard, Anasetti, Claudio, Bearman, Scott I., Beatty, Patrick, Bensinger, William I., Buckner, Dean C., Clift, Reginald A., Hansen, John A., Martin, Paul, Petersen, Finn B., Sanders, Jean E., Singer, Jack, Stewart, Patricia, Sullivan, Keith M., Witherspoon, Robert P., and Thomas, Donnall E.

Published
1990
Full Text
View/download PDF

19. Status of high-dose chemotherapy for breast cancer: A review

Author

Nieto, Yago, Champlin, Richard E., Wingard, John R., Vredenburgh, James J., Elias, Anthony D., Richardson, Paul, Glaspy, John, Jones, Roy B., Stiff, Patrick J., Bearman, Scott I., Cagnoni, Pablo J., McSweeney, Peter A., LeMaistre, C.Fred, Pecora, Andrew L., and Shpall, Elizabeth J.

Published
2000
Full Text
View/download PDF

21. Tacrolimus and Mycophenolate Mofetil as Post-Grafting Immunosuppression After Conditioning with Fludarabine and Low-Dose Total Body Irradiation for Recipients of HLA-Matched Sibling or Unrelated Donor Hematopoietic Cell Transplants in Patients with Paroxysmal Nocturnal Hemoglobinuria.

Author

Gregory, Tara, primary, Brunvand, Mark W., additional, McSweeney, Peter A., additional, Bearman, Scott I., additional, Maris, Michael, additional, and Matous, Jeffrey, additional

Published
2009
Full Text
View/download PDF

22. Intensive Dose-Dense Compared With High-Dose Adjuvant Chemotherapy for High-Risk Operable Breast Cancer: Southwest Oncology Group/Intergroup Study 9623

Author

Moore, Halle C.F., primary, Green, Stephanie J., additional, Gralow, Julie R., additional, Bearman, Scott I., additional, Lew, Danika, additional, Barlow, William E., additional, Hudis, Clifford, additional, Wolff, Antonio C., additional, Ingle, James N., additional, Chew, Helen K., additional, Elias, Anthony D., additional, Livingston, Robert B., additional, and Martino, Silvana, additional

Published
2007
Full Text
View/download PDF

24. Low Incidence of Acute Graft-VS.-Host Disease (GVHD) Using Tacrolimus (TAC) and Mycophenolate Mofetil (MMF) after Matched Sibling Donor (MSD) Non-Myeloablative Stem-Cell Transplants (NST) Conditioned with Fludarabine (FLU) and Low-Dose Total Body Irradiation (TBI).

Author

Nieto, Yago, primary, Patton, Nigel, primary, Hawkins, Timothy, primary, Spearing, Ruth, primary, Bearman, Scott I., primary, Rabinovitch, Rachel, primary, Zeng, Chan, primary, Baron, Anna, primary, and McSweeney, Peter A., primary

Published
2004
Full Text
View/download PDF

25. Phase II Feasibility and Pharmacokinetic Study of Concurrent Administration of Trastuzumab and High-Dose Chemotherapy in Advanced HER2+ Breast Cancer

Author

Nieto, Yago, primary, Vredenburgh, James J., additional, Shpall, Elizabeth J., additional, Bearman, Scott I., additional, McSweeney, Peter A., additional, Chao, Nelson, additional, Rizzieri, David, additional, Gasparetto, Christina, additional, Matthes, Steve, additional, Barón, Anna E., additional, and Jones, Roy B., additional

Published
2004
Full Text
View/download PDF

26. Prognostic Analysis of Early Lymphocyte Recovery in Patients with Advanced Breast Cancer Receiving High-Dose Chemotherapy with an Autologous Hematopoietic Progenitor Cell Transplant

Author

Nieto, Yago, primary, Shpall, Elizabeth J., additional, McNiece, Ian K., additional, Nawaz, Samia, additional, Beaudet, Julie, additional, Rosinski, Steve, additional, Pellom, Julie, additional, Slat-Vasquez, Victoria, additional, McSweeney, Peter A., additional, Bearman, Scott I., additional, Murphy, James, additional, and Jones, Roy B., additional

Published
2004
Full Text
View/download PDF

37. BONE MARROW METASTASES

Author

Shpall, Elizabeth J., primary, Gee, Adrian P., additional, Hogan, Christopher, additional, Cagnoni, Pablo, additional, Gehling, Ursula, additional, Hami, Lisa, additional, Franklin, Wilbur, additional, Bearman, Scott I., additional, Ross, Maureen, additional, and Jones, Roy B., additional

Published
1996
Full Text
View/download PDF

39. Stem cell isolation

Author

Shpall, Elizabeth J., primary, Gee, Adrian, additional, Cagnoni, Pablo J., additional, Hogan, Christopher, additional, Gehling, Ursula, additional, Hami, Lisa, additional, Franklin, Wilbur, additional, Bearman, Scott I., additional, Ross, Maureen, additional, and Jones, Roy B., additional

Published
1995
Full Text
View/download PDF

45. MARROW TRANSPLANTATION FROM HLA-MATCHED UNRELATED DONORS FOR TREATMENT OF HEMATOLOGIC MALIGNANCIES

Author

BEATTY, PATRICK G., primary, HANSEN, JOHN A., additional, LONGTON, GARY M., additional, THOMAS, E. DONNALL, additional, SANDERS, JEAN E., additional, MARTIN, PAUL J., additional, BEARMAN, SCOTT I., additional, ANASETTI, CLAUDIO, additional, PETERSDORF, EFFIE W., additional, MICKELSON, ERIC M., additional, PEPE, MARGARET S., additional, APPELBAUM, FREDRICK R., additional, BUCKNER, C. DEAN, additional, CLIFT, REGINALD A., additional, PETERSEN, FINN BO, additional, STEWART, PATRICIA S., additional, STORB, RAINER F., additional, SULLIVAN, KEITH M., additional, TESLER, MICHELE C., additional, and WITHERSPOON, ROBERT P., additional

Published
1991
Full Text
View/download PDF

49. Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome

Author

Richardson, Paul G., Murakami, Carol, Jin, Zhezhen, Warren, Diane, Momtaz, Parisa, Hoppensteadt, Deborah, Elias, Anthony D., Antin, Joseph H., Soiffer, Robert, Spitzer, Thomas, Avigan, David, Bearman, Scott I., Martin, Paul L., Kurtzberg, Joanne, Vredenburgh, James, Chen, Allen R., Arai, Sally, Vogelsang, Georgia, McDonald, George B., and Guinan, Eva C.

Abstract

Veno-occlusive disease (VOD) is the most common regimen-related toxicity accompanying stem cell transplantation (SCT). Severe VOD complicated by multisystem organ failure (MOF) remains almost uniformly fatal. Preliminary experience with defibrotide (DF), a single-stranded polydeoxyribonucleotide with fibrinolytic, antithrombotic, and anti-ischemic properties, in the treatment for severe VOD has suggested safety and activity. Eighty-eight patients who developed severe VOD after SCT were treated with DF under a defined treatment plan. At diagnosis, median bilirubin was 76.95 μM (4.5 mg/dL), median weight gain was 7%, ascites was present in 84%, and abnormal hepatic portal venous flow was present in 35%. At DF initiation, median bilirubin had increased to 215.46 μM (12.6 mg/dL), and MOF was present in 97%. DF was administered intravenously in doses ranging from 5 to 60 mg/kg per day for a median of 15 days. No severe hemorrhage or other serious toxicity related to DF was reported. Complete resolution of VOD was seen in 36%, with 35% survival at day +100. Predictors of survival included younger age, autologous SCT, and abnormal portal flow, whereas busulfan-based conditioning and encephalopathy predicted worse outcome. Decreases in mean creatinine and plasminogen activator inhibitor 1(PAI-1) levels during DF therapy predicted better survival. The complete response rate, survival to day +100, and absence of significant DF-associated toxicity in this largest patient cohort reported to date confirm the results of earlier studies. Certain features associated with successful outcome may correlate with DF-related treatment effects, and prospective evaluation of DF therapy for severe VOD should allow better definition of predictors of response or failure.

Published
2002
Full Text
View/download PDF

50. Treatment of Severe Veno-Occlusive Disease With Defibrotide: Compassionate Use Results in Response Without Significant Toxicity in a High-Risk Population

Author

Richardson, Paul G., Elias, Anthony D., Krishnan, Amrita, Wheeler, Catherine, Nath, Raj, Hoppensteadt, Debra, Kinchla, Nancy M., Neuberg, Donna, Waller, Edmund K., Antin, Joseph H., Soiffer, Robert, Vredenburgh, James, Lill, Michael, Woolfrey, Ann E., Bearman, Scott I., Iacobelli, Massimo, Fareed, Jawed, and Guinan, Eva C.

Abstract

Hepatic veno-occlusive disease (VOD) is the most common of the regimen-related toxicities accompanying stem cell transplantation (SCT). Despite aggressive therapies, including the combination of tissue plasminogen activator (t-PA) and heparin, severe VOD is almost uniformly fatal. Defibrotide (DF) is a polydeoxyribonucleotide with activity in several vascular disorders and, unlike t-PA and heparin, produces no systemic anticoagulant effects. Nineteen patients who developed severe VOD after SCT were treated with DF on a compassionate-use basis. Patients had clinically established VOD and met risk criteria predicting progression and fatality. At the initiation of DF, all 19 patients had evidence of multiorgan dysfunction; median bilirubin was 22.3 mg/dL, 12 patients had renal insufficiency (5 dialysis dependent), 14 required oxygen supplementation, and encephalopathy was present in 8 patients. Beginning a median of 6 days after diagnosis of VOD, DF was administered intravenously in doses ranging from 5 to 60 mg/kg/d for a planned minimum course of 14 days. In no case was DF discontinued for attributable toxicity. No severe hemorrhage related to DF administration was observed. Resolution of VOD (bilirubin <2 mg/dL with improvement in other symptoms and signs) was seen in 8 patients (42%). Six of 8 responders survived past day +100, contrasted with the 2% predicted survival reported in comparable patients. The observed response rate, survival to day +100, and absence of significant DF treatment-associated toxicity are compelling and warrant further evaluation. © 1998 by The American Society of Hematology.

Published
1998
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results